Ipratropium (EENT)

Brand names: Atrovent Nasal Spray
Drug class: Antineoplastic Agents , Antineoplastic Agents

Usage of Ipratropium (EENT)

Common Cold

Symptomatic relief of rhinorrhea associated with the common cold in adults and children ≥5 years of age. Does not relieve nasal congestion or sneezing.

Seasonal Allergic Rhinitis

Symptomatic relief of rhinorrhea associated with seasonal allergic rhinitis in adults and children ≥5 years of age. Does not relieve nasal congestion, sneezing, or itching eyes.

Perennial Rhinitis

Symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children ≥6 years of age. Does not relieve nasal congestion, sneezing, or postnasal drip.

Relate drugs

How to use Ipratropium (EENT)

Administration

Intranasal Administration

Administer in each nostril 2–4 times daily using spray pump supplied by the manufacturer.

Prime pump before first dose with 7 sprays; if used regularly, no further priming required. If not used for >24 hours, reprime with 2 sprays; if not used for >7 days, reprime with 7 sprays.

Dosage

Intranasal spray pump delivers 0.07 mL of solution per actuation.

Ipratropium bromide 0.03% nasal spray delivers 21 mcg of ipratropium bromide per spray and about 345 sprays per bottle.

Ipratropium bromide 0.06% nasal spray delivers 42 mcg of ipratropium bromide per spray and about 165 sprays per bottle.

Pediatric Patients

Common Cold Intranasal

Children 5–11 years of age: 84 mcg (2 sprays of the 0.06% solution) in each nostril 3 times daily.

Children ≥12 years of age: 84 mcg (2 sprays of the 0.06% solution) in each nostril 3 or 4 times daily.

Seasonal Allergic Rhinitis Intranasal

Children ≥5 years of age: 84 mcg (2 sprays of the 0.06% solution) in each nostril 4 times daily.

Perennial Rhinitis Intranasal

Children ≥6 years of age: 42 mcg (2 sprays of the 0.03% solution) in each nostril 2 or 3 times daily.

Adults

Common Cold Intranasal

84 mcg (2 sprays of the 0.06% solution) in each nostril 3 or 4 times daily.

Seasonal Allergic Rhinitis Intranasal

84 mcg (2 sprays of the 0.06% solution) in each nostril 4 times daily.

Perennial Rhinitis Intranasal

42 mcg (2 sprays of the 0.03% solution) in each nostril 2 or 3 times daily.

Prescribing Limits

Pediatric Patients

Common Cold Intranasal

Safety and efficacy beyond 4 days not established.

Seasonal Allergic Rhinitis Intranasal

Safety and efficacy beyond 3 weeks not established.

Adults

Common Cold Intranasal

Safety and efficacy beyond 4 days not established.

Seasonal Allergic Rhinitis Intranasal

Safety and efficacy beyond 3 weeks not established.

Warnings

Contraindications

  • Known hypersensitivity to ipratropium or any ingredient in the formulation, or to atropine or its derivatives.

    • Warnings/Precautions

    Sensitivity Reactions

    Hypersensitivity Reactions

    Immediate hypersensitivity reactions, including urticaria, angioedema, rash, bronchospasm, and oropharyngeal edema, may occur.

    General Precautions

    Ocular Effects

    Caution in patients with angle-closure glaucoma. Ocular pain or precipitation or worsening of angle-closure glaucoma reported following inadvertent contact of the drug with the eyes.

    Genitourinary Effects

    Caution in patients with prostatic hypertrophy or bladder neck obstruction.

    Specific Populations

    Pregnancy

    Category B.

    Lactation

    Not known whether ipratropium is distributed into milk following intranasal administration. Caution advised.

    Pediatric Use

    Safety established based on studies in children.

    Efficacy based on extrapolation from studies in adults with perennial rhinitis and adults and adolescents with common cold or seasonal allergic rhinitis and on the likelihood that the disease course, pathophysiology, and the drug’s effect in children are similar to those in adults.

    Safety and efficacy of 0.03% nasal spray not established in children <6 years of age.

    Safety and efficacy of 0.06% nasal spray not established in children <5 years of age.

    Common Adverse Effects

    Nasal dryness, epistaxis.

    What other drugs will affect Ipratropium (EENT)

    Limited systemic absorption of intranasal ipratropium minimizes potential for interactions with systemically administered drugs.

    Antimuscarinic Agents

    Potential for additive pharmacologic effect with other antimuscarinic agents, including orally inhaled ipratropium.

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords